Toward the greater good
Launched in 2021 by Roblox founder and CEO David Baszucki and best-selling author Jan Ellison Baszucki, Baszucki Group leverages private giving, impact investing, advocacy, storytelling and community building to drive foundational change.
A primary objective of Baszucki Group is to transform mental health outcomes, beginning with bipolar disorder, by supporting initiatives at the intersection of metabolism, psychiatry and neuroscience. Our investments in democracy, conservation and our communities are synergistic with our life sciences initiatives.
Our work emphasizes innovative platforms and programs in five primary areas:
Introducing Metabolic Mind™
Jan, Dave and Matt Baszucki share their family’s story of recovery from mental illness aided by a ketogenic metabolic therapy with 100 years of evidence in epilepsy. Experts in the emerging fields of metabolic psychiatry and metabolic neuroscience discuss new approaches to understanding and treating mental disorders.
Metabolic Mind™ is a nonprofit initiative incubated by Baszucki Group. Its mission over time will be to provide resources and build community in metabolic psychiatry.
News & Views
Why Three Deep-Pocketed Funders Joined Forces to Take on Bipolar Disorder
October 3, 2022 — Three families who have been personally affected by bipolar disorder came together to bring new treatment options to families across the world. BD², Breakthrough Discoveries for Bipolar Disorder, will serve as a global platform to coordinate science across disciplines and national borders to tackle this complex and still poorly understood disorder.
Sergey Brin, Roblox’s David Baszucki And Kent Dauten Of Keystone Capital Commit $150 Million To Fight Bipolar Disorder
September 12, 2022 — Google cofounder Sergey Brin; Roblox founder David Baszucki and his wife, author Jan Ellison Baszucki; and Keystone Capital chairman Kent Dauten and his wife Liz Dauten each committed $50 million over five years to a global endeavor called BD² Breakthrough Discoveries for Thriving with Bipolar Disorder.